• Eileen M Bulger, Susanne May, Jeffery D Kerby, Scott Emerson, Ian G Stiell, Martin A Schreiber, Karen J Brasel, Samuel A Tisherman, Raul Coimbra, Sandro Rizoli, Joseph P Minei, J Steven Hata, George Sopko, David C Evans, David B Hoyt, and ROC investigators.
• Department of Surgery, University of Washington, Seattle, WA, USA.ebulger@u.washington.edu
• Ann. Surg. 2011 Mar 1; 253 (3): 431441431-41.

ObjectiveTo determine whether out-of-hospital administration of hypertonic fluids would improve survival after severe injury with hemorrhagic shock.BackgroundHypertonic fluids have potential benefit in the resuscitation of severely injured patients because of rapid restoration of tissue perfusion, with a smaller volume, and modulation of the inflammatory response, to reduce subsequent organ injury.MethodsMulticenter, randomized, blinded clinical trial, May 2006 to August 2008, 114 emergency medical services agencies in North America within the Resuscitation Outcomes Consortium.Inclusion Criteriainjured patients, age ≥ 15 years with hypovolemic shock (systolic blood pressure ≤ 70 mm Hg or systolic blood pressure 71-90 mm Hg with heart rate ≥ 108 beats per minute). Initial resuscitation fluid, 250 mL of either 7.5% saline per 6% dextran 70 (hypertonic saline/dextran, HSD), 7.5% saline (hypertonic saline, HS), or 0.9% saline (normal saline, NS) administered by out-of-hospital providers. Primary outcome was 28-day survival. On the recommendation of the data and safety monitoring board, the study was stopped early (23% of proposed sample size) for futility and potential safety concern.Results : A total of 853 treated patients were enrolled, among whom 62% were with blunt trauma, 38% with penetrating. There was no difference in 28-day survival-HSD: 74.5% (0.1; 95% confidence interval [CI], -7.5 to 7.8); HS: 73.0% (-1.4; 95% CI, -8.7-6.0); and NS: 74.4%, P = 0.91. There was a higher mortality for the postrandomization subgroup of patients who did not receive blood transfusions in the first 24 hours, who received hypertonic fluids compared to NS [28-day mortality-HSD: 10% (5.2; 95% CI, 0.4-10.1); HS: 12.2% (7.4; 95% CI, 2.5-12.2); and NS: 4.8%, P < 0.01].ConclusionAmong injured patients with hypovolemic shock, initial resuscitation fluid treatment with either HS or HSD compared with NS, did not result in superior 28-day survival. However, interpretation of these findings is limited by the early stopping of the trial.Clinical Trial RegistrationClinical Trials.gov, NCT00316017.

28 keywords...

hide…